CGM

EQS-News: CGM proposes dividend of EUR 1.00 to be passed at virtual AGM in May

Retrieved on: 
Wednesday, April 10, 2024
CGM, Annual, EUR, Supervisory board, Travel, AGM, News, CO2, Annual report, Artificial intelligence

Virtual Annual General Meeting on May 22, 2024

Key Points: 
  • Virtual Annual General Meeting on May 22, 2024
    Koblenz - CompuGroup Medical SE & Co. KGaA (CGM) will hold its Annual General Meeting on May 22 again virtually this year.
  • The virtual AGM format will enable a direct interaction between shareholders and management by means of video communication and digital communication channels.
  • It will also make it easier for international investors to participate without additional travel expenses and an associated reduction in CO2 emissions.
  • The general partner and the Supervisory Board propose a dividend of EUR 1.00 per share to the Annual General Meeting, this is EUR 0.50 more than previous year.

EQS-News: CompuGroup Medical US announces CEO transition

Retrieved on: 
Wednesday, April 10, 2024
CGM, Acquisition, News, LIS, Electronic health record, Clearing house

Austin, TX – Underlining the commitment to its second largest market worldwide by revenue, CompuGroup Medical announces the appointment of Benedikt Brueckle as its new Chief Executive Officer for the US, effective January 1, 2025.

Key Points: 
  • Austin, TX – Underlining the commitment to its second largest market worldwide by revenue, CompuGroup Medical announces the appointment of Benedikt Brueckle as its new Chief Executive Officer for the US, effective January 1, 2025.
  • "We are very grateful for Derek Pickell's leadership and contributions to CompuGroup Medical US", said Michael Rauch, CEO of CompuGroup Medical SE & Co. KGaA.
  • Derek Pickell, the outgoing US CEO, has led CompuGroup Medical US with distinction, overseeing steady growth and expansion.
  • Benedikt Brueckle has been with CompuGroup Medical for more than 13 years and led the acquisition of eMDs in 2020.

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
Thursday, April 4, 2024
CGM, Consultant, Negotiation, Conference, Growth, Data analysis, HIV, Himawari (satellites), Diabetes, World Health Organization, Acquisition, American depositary receipt, Diagnosis of HIV/AIDS, Units of paper quantity, Clinical trial, Injection, Balance sheet, Waveform, Pharmaceutical industry

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

Rimidi Launches New Partnership Program, The Rimidi Care Network, to Increase Access to Remote Monitoring Services

Retrieved on: 
Tuesday, March 19, 2024
CGM, Conditional sentence, Remote patient monitoring, Communication, Partnership, Patient, Hospital, Doctor of Philosophy, MD, BHI, Chronic care management, CCM, EHR, Medicare, RPM, Health, RTM, Plague, Nursing

As a result, the new partnership program makes it easier for providers to expand the bandwidth of their staff and scale remote monitoring programs.

Key Points: 
  • As a result, the new partnership program makes it easier for providers to expand the bandwidth of their staff and scale remote monitoring programs.
  • “With The Rimidi Care Network, we can extend access to remote clinical monitoring services for healthcare providers and ultimately help them improve engagement outcomes for patients with chronic conditions.”
    Founding Rimidi Care Network Partners include:
    GatewayMD – a turnkey RPM, CCM, and BHI servicing and management company that enhances chronic disease management between patients and their providers, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) services.
  • Quest Health Services RPM – an industry-leading remote patient monitoring program and solution designed to offer the best experience possible for healthcare workers and patients, specializing in continuous glucose monitoring.
  • To learn more about The Rimidi Care Network and how to implement remote monitoring services into your practice, or for additional information on becoming a partner, visit rimidi.com/lp/rimidi-care-network .

Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance

Retrieved on: 
Monday, March 18, 2024
CGM, Organization, Cell, DEKA, Entrepreneurship, AID, Insulin, Diabetes, Patient, Life, Pancreas, FDA, Medical laboratory scientist, Food, Pharmaceutical industry

MANCHESTER, N.H., March 18, 2024 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool.

Key Points: 
  • MANCHESTER, N.H., March 18, 2024 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool.
  • The twiist AID system, which will be commercialized by Sequel Med Tech, LLC, is the first drug delivery system that directly measures the volume and flow of insulin delivered with every micro-dose.
  • “The clearance of the twiist AID system is a pivotal first step in Sequel’s quest to make day-to-day life easier for people with type 1 diabetes.
  • The twiist system was designed from the start to integrate with the latest available innovation, and it represents the next generation of insulin delivery,” said Kamen.

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
CGM, Administration, G42, IROS, Type 2 diabetes, Incidence, Insulin, Patient, Level 2, G&A, Doctor of Philosophy, MD, VTV, Clinical research associate, Research and development, Therapy, JDRF, PIPE, Safety, Saṃsāra, FDA, Pharmaceutical industry

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members.
  • HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
  • Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2023, was $20.3 million or $9.71 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $19.2 million or $9.98 per basic share.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Dexcom Publishes Annual Sustainability Report

Retrieved on: 
Wednesday, April 3, 2024
Diabetes, Medical Devices, Environment, Health, Sustainability, CGM, Science Based Targets initiative, Integrity, DXCM, Caregiver, Global health, Science, Targets

DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report.
  • This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.
  • The sustainability report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.
  • Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at investors.dexcom.com .

United States Self-Monitoring Blood Glucose Devices Market Share, Size, Trends, Analysis and Forecasts 2024-2032: Accuracy, Affordability, Accessibility Emerge as Key Priorities for Manufacturers - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Medical Devices, Health, CGM, Insulin, Diabetes, COVID-19, Patient, Artificial intelligence, Wearable technology, Digital health, Telehealth, USD, Data management, Ageing, The, Medical device

How is the United States self-monitoring blood glucose devices market anticipated to evolve during the forecast period 2024 - 2032?

Key Points: 
  • How is the United States self-monitoring blood glucose devices market anticipated to evolve during the forecast period 2024 - 2032?
  • What are the main drivers and restraints in the United States self-monitoring blood glucose devices market?
  • What are the major deals happening in the United States self-monitoring blood glucose devices market?
  • What is the reimbursement scenario of the products offered in the United States self-monitoring blood glucose devices market?

Global Smart Insulin Pens Market 10 Year Forecast Report 2024-2034 - A USD 2.30 Billion Market by 2034 with a 10% CAGR During 2024-2034

Retrieved on: 
Thursday, March 28, 2024
Diabetes, CGM, Sanofi, Eli Lilly, Prevalence, Dexcom, Data analysis, Incidence, Partnership, Insulin, Patient, Continuous glucose monitor, Prescription, Novo Nordisk, Investment, Research report, USD, Pharmaceutical industry

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.
  • The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034.
  • Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens.
  • Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens.